Dr. Reddy's Laboratories Ltd. closed 11.64% short of its 52-week high of 1,377.95 rupees, which the company reached on June 12th.

Dr. Reddy's Laboratories Ltd. 500124 shares shed 2.13% to 1,254.65 Indian rupees Monday, on what proved to be an all-around rough trading session for the stock market, with the BSE SENSEX Index 1 ...

Dr. Reddy’s Laboratories has launched ‘Obeda’, an injectable semaglutide therapy for diabetes and weight management in India.

Dr Reddy’s launches Obeda, a generic semaglutide for diabetes management, priced at ₹4,200 per month in India.

Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the ...

Stay informed with the Dr Reddys Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a ...

Corona Remedies announced the acquisition of Wokadine brand from Dr. Reddy's Laboratories to strengthen its presence in targeted specialty segment and offer wider accessibility.

Dr Reddy Q4 Results 2025 Date, Dr Reddy Dividend: The earnings season for the January-March quarter of FY 2024-25 is about to begin and therefore, several companies have started sharing their ...

Add Yahoo as a preferred source to see more of our stories on Google. SHREVEPORT, La. (KTAL/KMSS) – Dr. Reddy’s Laboratories, a global pharmaceutical company, recently closed in early 2025 due to ...

Dr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian ...

Dr Reddy’s Lab targets ₹1,315 after launching a premium GLP-1 product, Obeda, positioning for growth in India’s market.